Literature DB >> 11718320

Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine.

J Ott1.   

Abstract

Summarized are psychonautic bioassays (human self-experiments) of pharmañopo--crystalline bufotenine (5-HO-DMT; 5-hydroxy-N,N-dimethyltryptamine; dimethylserotonine), at times combined with harmaline or harmine-via intranasal, sublingual, intrarectal, pulmonary (inhaled vapor) and oral routes. This is done by way of pharmacological modeling of diverse South American shamanic inebriants, principally the snuffs ñopolyopo and cebílhaáj, prepared from seeds of Anadenanthera peregrina var. peregrina and A. colubrina var. Cebil, respectively. Psychoptic (visionary) activity of bufotenine has been established and the 1967 Holmstedt-Lindgren hypothesis of the paricá effect-intranasal potentiation of tryptamines by concomitant administration of monoamine-oxidase-inhibiting (MAOI) beta-carbolines from stems of Banisteriopsis caapi admixed with the snuffs-has been confirmed by 25 psychonautic bioassays. Salient phytochemical and psychonautic literature is reviewed, and isolation of bufotenine from Anadenanthera seeds detailed (with one table and eight references).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11718320     DOI: 10.1080/02791072.2001.10400574

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  9 in total

1.  Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America.

Authors:  Melanie J Miller; Juan Albarracin-Jordan; Christine Moore; José M Capriles
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-06       Impact factor: 11.205

2.  Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Bioanalysis       Date:  2009-04       Impact factor: 2.681

3.  Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.

Authors:  Hong-Wu Shen; Chao Wu; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2010-03-03       Impact factor: 5.858

Review 4.  Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Jerrold C Winter; Ai-Ming Yu
Journal:  Curr Drug Metab       Date:  2010-10       Impact factor: 3.731

Review 5.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

Review 6.  Recreational use, analysis and toxicity of tryptamines.

Authors:  Roberta Tittarelli; Giulio Mannocchi; Flaminia Pantano; Francesco Saverio Romolo
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

7.  Biological Effects and Biodistribution of Bufotenine on Mice.

Authors:  Hugo Vigerelli; Juliana Mozer Sciani; Maria Andrea Camarano Eula; Luciana Almeida Sato; Marta M Antoniazzi; Carlos Jared; Daniel C Pimenta
Journal:  Biomed Res Int       Date:  2018-05-31       Impact factor: 3.411

Review 8.  Toxicology and Analysis of Psychoactive Tryptamines.

Authors:  Sara Malaca; Alfredo Fabrizio Lo Faro; Alice Tamborra; Simona Pichini; Francesco Paolo Busardò; Marilyn A Huestis
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

9.  Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT.

Authors:  Vanja Dakic; Juliana Minardi Nascimento; Rafaela Costa Sartore; Renata de Moraes Maciel; Draulio B de Araujo; Sidarta Ribeiro; Daniel Martins-de-Souza; Stevens K Rehen
Journal:  Sci Rep       Date:  2017-10-09       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.